Tu Jie, Liu Na, Huang Yahui, Yang Wanzhen, Sheng Chunquan
School of Pharmacy, Second Military Medical University, Shanghai 200433, China.
Acta Pharm Sin B. 2022 Nov;12(11):4056-4074. doi: 10.1016/j.apsb.2022.08.001. Epub 2022 Aug 12.
is emerging as a major global threat to human health. infections are associated with high mortality due to intrinsic multi-drug resistance. Currently, therapeutic options for the treatment of infections are rather limited. We aim to provide a comprehensive review of current strategies, drug candidates, and lead compounds in the discovery and development of novel therapeutic agents against . The drug resistance profiles and mechanisms are briefly summarized. The structures and activities of clinical candidates, drug combinations, antifungal chemosensitizers, repositioned drugs, new targets, and new types of compounds will be illustrated in detail, and perspectives for guiding future research will be provided. We hope that this review will be helpful to prompting the drug development process to combat this fungal pathogen.
正成为对人类健康的重大全球威胁。由于其内在的多重耐药性,感染与高死亡率相关。目前,治疗感染的治疗选择相当有限。我们旨在全面综述针对感染发现和开发新型治疗药物的当前策略、候选药物和先导化合物。简要总结了耐药谱和机制。将详细说明临床候选药物、药物组合、抗真菌化学增敏剂、重新定位的药物、新靶点和新型化合物的结构和活性,并提供指导未来研究的展望。我们希望这篇综述将有助于推动对抗这种真菌病原体的药物开发进程。